Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Halozyme Therapeutics, Inc. - Common Stock (NQ: HALO )

55.28 -0.66 (-1.18%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Halozyme Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
BeiGene Stock Meets 80-Plus RS Rating Benchmark
One key metric to look for in a stock is an 80-plus Relative Strength Rating. BeiGene stock just hit that mark, with a jump to 84 Wednesday. 
Via Investor's Business Daily
BridgeBio Pharma Stock Earns 87 RS Rating
BridgeBio Pharma stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an increase from 64 to 87. 
Via Investor's Business Daily
Analyst Expectations For Halozyme Therapeutics's Future
Via Benzinga
SpringWorks Therapeutics Stock Gets A RS Rating Lift
The Relative Strength (RS) Rating for SpringWorks Therapeutics stock entered a higher percentile Wednesday, as it got a lift from 62 to 76. 
Via Investor's Business Daily
Despite its growth, NASDAQ:HALO remains within the realm of affordability.
Don't overlook HALOZYME THERAPEUTICS INC (NASDAQ:HALO)—a stock with solid growth prospects and a reasonable valuation. 
Via Chartmill
In a market where value is scarce, NASDAQ:HALO offers a refreshing opportunity with its solid fundamentals.
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is an undervalued gem with solid fundamentals. 
Via Chartmill
9 Analysts Have This To Say About Halozyme Therapeutics
Via Benzinga
Is NASDAQ:HALO on the Verge of a Major Breakout as a Strong Growth Stock?
Why HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Is a Promising High-Growth Stock in the Midst of Consolidation. 
Via Chartmill
Looking for growth without the hefty price tag? Consider NASDAQ:HALO.
NASDAQ:HALO, a growth stock which is not overvalued. 
Via Chartmill
In a market where value is scarce, NASDAQ:HALO offers a refreshing opportunity with its solid fundamentals.
For those who appreciate value investing, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is a compelling option with its solid fundamentals. 
Via Chartmill
(HALO) - Analyzing Halozyme Therapeutics's Short Interest
Via Benzinga
Halozyme Withdraws Evotec Bid After Rebuff, Reaffirms Strong Growth Outlook
Halozyme stock rises after withdrawing its €2B acquisition offer for Evotec, while reaffirming strong growth outlook for 2024. 
Via Benzinga
While growth is established for NASDAQ:HALO, the stock's valuation remains reasonable.
NASDAQ:HALO stands out as a growth opportunity that won't break the bank. 
Via Chartmill
NASDAQ:HALO is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Despite its impressive fundamentals, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) remains undervalued. 
Via Chartmill
Breaking Down Halozyme Therapeutics: 10 Analysts Share Their Views
Via Benzinga
Looking Into Halozyme Therapeutics's Recent Short Interest
Via Benzinga
A Look Ahead: Halozyme Therapeutics's Earnings Forecast
Via Benzinga
Unveiling 12 Analyst Insights On Halozyme Therapeutics
Via Benzinga
Exploring the Growth Potential of NASDAQ:HALO as It Nears a Breakout.
Exploring the Growth Potential of HALOZYME THERAPEUTICS INC (NASDAQ:HALO) as It Nears a Breakout. 
Via Chartmill
Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion
Halozyme offers to acquire Evotec for €11.00 per share, boosting Evotec's value to €2 billion. The merger aims to enhance Halozyme's revenue growth and portfolio. 
Via Benzinga
Amazon Posts Upbeat Results, Joins Cardinal Health, Waters, Atlassian, Charter Communications, MasTec And Other Big Stocks Moving Higher On Friday
Via Benzinga
Why Charter Communications Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Despite its growth, NASDAQ:HALO remains within the realm of affordability.
Despite its growth, NASDAQ:HALO remains within the realm of affordability. 
Via Chartmill
Despite its impressive fundamentals, NASDAQ:HALO remains undervalued.
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is an undervalued gem with solid fundamentals. 
Via Chartmill
Investors seeking growth at a reasonable cost should explore NASDAQ:HALO.
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is showing good growth, while it is not too expensive. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Investors should take notice of NASDAQ:HALO—it offers a great deal for the fundamentals it presents.
For those who appreciate value investing, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is a compelling option with its solid fundamentals. 
Via Chartmill
A Glimpse Into The Expert Outlook On Halozyme Therapeutics Through 12 Analysts
Via Benzinga
NASDAQ:HALO is showing good growth, while it is not too expensive.
Investors should take note ofHALOZYME THERAPEUTICS INC (NASDAQ:HALO), a growth stock that remains attractively priced. 
Via Chartmill
NASDAQ:HALO is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) appears to be flying under the radar despite its strong fundamentals. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.